Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy

NCT06570915 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No eligeble patients

Conditions

ALL, Adult

Interventions

DRUG: Daratumumab Injection

Sponsor

Institute of Hematology & Blood Diseases Hospital, China